Journal article
Influence of natural and synthetic histone deacetylase inhibitors on chromatin
PV Licciardi, FAA Kwa, K Ververis, N Di Costanzo, A Balcerczyk, ML Tang, A El-Osta, TC Karagiannis
Antioxidants and Redox Signaling | MARY ANN LIEBERT, INC | Published : 2012
Abstract
Significance: Histone deacetylase inhibitors (HDACIs) have emerged as a new class of anticancer therapeutics. The hydroxamic acid, suberoylanilide hydroxamic acid (Vorinostat, Zolinza™), and the cyclic peptide, depsipeptide (Romidepsin, Istodax™), were approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma in 2006 and 2009, respectively. At least 15 HDACIs are currently undergoing clinical trials either alone or in combination with other therapeutic modalities for the treatment of numerous hematological and solid malignancies. Recent Advances: The potential utility of HDACIs has been extended to nononcologic applications, including autoimmune d..
View full abstractGrants
Funding Acknowledgements
The support of the Australian Institute of Nuclear Science and Engineering is acknowledged. T.C.K. was the recipient of AINSE awards. The authors acknowledge JDRF Fellowship support and support from the Foundation for Polish Science. Epigenomic Medicine and Human Epigenetics Labs are supported by the National Health and Medical Research Council of Australia. K.V. is supported by a Baker IDI postgraduate scholarship. Supported in part by the Victorian Government's Operational Infrastructure Support Program. The authors would like to acknowledge the use of the facilities provided by Monash Micro Imaging @ AMREP and, particularly, the expert assistance from Drs. Stephen Cody and Iska Carmichael.